At what enterprise value was IONISOS acquired in 2019?

During the acquisition of IONISOS by 3I in 2019, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of IONISOS when it was acquired by 3I?

The estimated EV/EBITDA multiple for IONISOS is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was IONISOS acquired by 3I?

IONISOS was acquired by 3I in 2019.

What was the revenue of IONISOS at the time of the deal?

The revenue of IONISOS at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of IONISOS during the acquisition?

IONISOS's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the IONISOS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the IONISOS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/3i-infrastructure-mise-220-m-pour-relayer-ardian-dans-ionisos-1040733

← DATABASE

Home Database Healthcare & PharmaIONISOS

07/2019

IONISOS acquired by 3I

FRANCE Life Sciences / Pharma & Biotech / CDMO EV 300M - 700M EUR

Context

Ionisos, a leading European specialist in cold sterilization services, has entered its fifth LBO cycle following its acquisition by 3i Infrastructure. The London-listed investor is deploying �220 million to acquire up to 100% of the company's equity from Ardian Expansion, which had held the asset since 2016. The remaining shares are held by the management team.

IONISOS, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

IONISOS, a specialist in gamma sterilization, ebeam, X-rays and ethylene oxide sterilization, offers its ionizing radiation and EO gas treatment services to professionals in the medical, pharmaceutical, veterinary, cosmetics and agri-food packaging industries.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2019	SAGARD	STERIMED	FRANCE	Medical Consumables
08/2019	PERMIRA	CAMBREX CORPORATION	UNITED STATES	CDMO
07/2019	PERMIRA	QUOTIENT SCIENCES	UNITED KINGDOM	CDMO
05/2019	ARDIAN	SINTETICA	SWITZERLAND	Pharma & Biotech
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Generics / Labs
04/2019	EURAZEO	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
12/2018	MERCK & CO.	ANTELLIQ	FRANCE	Animal Health
11/2018	ARDIAN	NEOPHARMED GENTILI	ITALY	Generics / Labs
10/2018	ASTORG	NEMERA	FRANCE	Medical Consumables
10/2018	BRIDGEPOINT	HTL BIOTECHNOLOGY	FRANCE	CDMO

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IONISOS by 3I are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: 3i